Jay Allen Sanford 8 p.m., Jan. 18
Sequenom Stock Soars on Fetal Sex Test
Stock of biotech Sequenom jumped 16.37% to $5.26 today (Feb. 16) as the company launched its fetal test for sex determination. The company says the test is noninvasive, requiring only a blood sample from the mother, and it makes the sex determination in the first trimester. Reuters points out that the test employs the company's SEQureDx technology, which had been suspended over an employee's mishandling of research and data. In April, the company shelved introduction of a Down syndrome test and said it was no longer relying on previous test data related to SEQureDx.